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Abstract
Background Biological characterisation of breast cancer subtypes is essential as it informs treatment regimens especially as 
different subtypes have distinct locoregional patterns. This is related to metabolic phenotype, where altered cellular metabo-
lism is a fundamental adaptation of cancer cells during rapid proliferation. In this context, the metabolism of the essential 
branched-chain amino acids (BCAAs), catalysed by the human branched-chain aminotransferase proteins (hBCAT), offers 
multiple benefits for tumour growth. Upregulation of the cytosolic isoform of hBCAT (hBCATc), regulated by c-Myc, has 
been demonstrated to increase cell migration, tumour aggressiveness and proliferation in gliomas, ovarian and colorectal 
cancer but the importance of the mitochondrial isoform, hBCATm has not been fully investigated.
Methods Using immunohistochemistry, the expression profile of metabolic proteins (hBCAT, IDH) was assessed between 
breast cancer subtypes, HER2 + , luminal A, luminal B and TNBC. Correlations between the percentage and the intensity 
of protein expression/co-expression with clinical parameters, such as hormone receptor status, tumour stage, lymph-node 
metastasis and survival, were determined.
Results We show that hBCATc expression was found to be significantly associated with the more aggressive HER2 + and 
luminal B subtypes, whilst hBCATm and IDH1 associated with luminal A subtype. This was concomitant with better prog-
nosis indicating a differential metabolic reliance between these two subtypes, in which enhanced expression of IDH1 may 
replenish the α-ketoglutarate pool in cells with increased hBCATm expression.
Conclusion The cytosolic isoform of BCAT is associated with tumours that express HER2 receptors, whereas the mito-
chondrial isoform is highly expressed in tumours that are ER + , indicating that the BCAT proteins are regulated through 
different signalling pathways, which may lead to the identification of novel targets for therapeutic applications targeting 
dysregulated cancer metabolism.
Keywords BCAT  · IDH · HER2 +  · Luminal A · Breast cancer
Abbreviations
BCAA  Branched-chain amino acids
BCAT  Branched-chain aminotransferase
DAB  3.3′-Diaminobenzidin
hBCATc  Human cytosolic branched-chain 
aminotransferase
hBCATm  Human mitochondrial branched-chain 
aminotransferase
BCKA  Branched-chain α-ketoacids
BCKDC  Branched-chain α-keto acid dehydrogenase 
enzyme complex
ER  Oestrogen
HER2  Human epidermal growth factor receptor-2
PR  Progesterone receptor
TNBC  Triple-negative breast cancer
IDH  Isocitrate dehydrogenase
2-HG  R-2-hydroxyglutarate
TBS  Tris-buffered saline
TCA  Tricarboxylic acid
 * Myra E. Conway 
 myra.conway@uwe.ac.uk
1 Faculty of Health and Life Sciences, University of the West 
of England, Coldharbour Lane, Bristol BS16 1QY, UK
2 Department of Pathology, Faculty of Medicine, Umm 




Breast cancer is the most common malignancy in women 
accounting for almost one in four cancer cases and is 
responsible for approximately 627,000 deaths each year 
globally [1]. It is a heterogeneous disease with several 
distinctive molecular subtypes which are defined by the 
status of oestrogen receptor (ER), progesterone receptor 
(PR) and overexpression/amplification of human epider-
mal growth factor receptor 2 (HER2) [2]. Molecular profil-
ing has led to the identification of four intrinsic molecular 
subtypes; luminal A, luminal B, HER2 + and triple-nega-
tive breast cancer (TNBC; ER-/PR-/HER2-) which repre-
sent biologically distinct disease entities [3, 4]. Luminal 
A breast cancers are characterized by high expression of 
luminal epithelial genes and low expression of Ki-67 [3], 
unlike Luminal B breast cancers, which have higher Ki-67 
expression. Luminal B sub-type also has lower expres-
sion of several luminal-related genes (such as ESR1 or 
FOXA1), genomic instability and a higher frequency of 
TP53 gene mutations associated with a worse prognosis 
and a higher risk of relapse than luminal A breast cancers 
[4–6]. Both luminal A and luminal B are characterised by 
the expression of the hormone receptors ER and PR, whilst 
a proportion of luminal B tumours are HER2-enriched [2]. 
HER2 + breast cancer is characterised by HER2 amplifica-
tion and the low expression of luminal and basal clusters 
[2, 3] whilst TNBC is characterised by tumours that lack 
the expression of ER and PR, the absence of HER2 over-
expression, and high expression of Ki-67 [2].
Prognosis and treatment strategies vary greatly between 
breast cancer molecular subtypes due to the activation of 
different oncogenic pathways [7]. A significant improve-
ment in breast cancer survival rates through the introduc-
tion of therapies that target hormone receptors, such as 
Tamoxifen (targets ER + tumours) and Trastuzumab (tar-
gets the HER2 tumours), has been reported [8, 9]. Despite 
the advancement in HER2-targeted therapy, HER2 con-
tinues to be one of the most aggressive subtypes of breast 
cancer with high mortality rates [10]. Moreover, breast 
cancer recurrence is a common contributor to breast can-
cer death rates either by metastasis or chemo-resistance 
[11, 12]. There is, therefore, an unmet need for the identi-
fication of novel therapeutic targets downstream of these 
growth receptors, which may improve the therapeutic 
efficiency.
Altered cellular metabolism is a fundamental adapta-
tion of cancer during disease development [13]. Many 
metabolic pathways have been reported to be dysregulated 
in breast cancer leading to metabolite addiction, such as 
dependency on glutamine for tumour growth, which can be 
exploited in cancer therapy [14, 15]. This reprogramming 
of cell metabolism in breast cancer is initiated by activa-
tion of oncogenes, such as c-Myc, which plays a central 
role in orchestrating proliferation, metabolism and dif-
ferentiation. A target of c-Myc is the human cytosolic 
branched-chain aminotransferase protein (hBCATc). The 
hBCAT proteins exist in two main isoforms, the mitochon-
drial hBCAT isoform (hBCATm protein, BCAT2 gene) is 
widely expressed in most tissues, whereas the cytosolic 
hBCAT (hBCATc protein, BCAT1 gene) is restricted to 
highly specialised tissues including brain and placenta 
[16]. Increased levels of the BCAT gene, BCAT1 have 
been extensively reported in malignancies including glio-
mas [17, 18], ovarian [19], colorectal [20], gastric cancer 
[21], nasopharyngeal carcinomas [22], breast cancer [23] 
and chronic myeloid leukemia (CML) [24]. In gliomas, 
increased hBCATc and hBCATm expression has been lim-
ited to gliomas with wild-type isocitrate dehydrogenase 1 
(IDH1), cytosolic and IDH2, mitochondrial [17, 18]. As a 
result, perturbations in BCAA metabolism have also been 
a subject of increased interest [25] where upregulation of 
hBCATc has been reported to increase cell proliferation 
and migration in ER-negative breast cancer cells [23]. Our 
recent study showed that hBCATc regulates TNBC cell 
proliferation migration and invasion through the IGF-1/
insulin PI3K/Akt pathway, culminating in the upregula-
tion of FOXO3a and Nrf2, pointing to a novel therapeutic 
target for breast cancer treatment [26].
The IDH enzymes which catalyse the oxidative decar-
boxylation of isocitrate to produce the TCA intermedi-
ate α-ketoglutarate, also support cell growth [27]. IDH 
mutations have been found to result in neomorphic activ-
ity to metabolize α-ketoglutarate to R-2-hydroxyglutarate 
(2HG), an oncometabolite, which accumulates and inhib-
its chromatin-modifying enzymes and has been demon-
strated to inhibit hBCATc expression in gliomas [28–31]. 
In contrast to gliomas, there is little evidence of IDH1 
mutations in breast cancer, with only one reported case 
noted [32, 33]. The association between IDH and hBCAT 
expression has not been evaluated in breast cancer, inves-
tigation of which may uncover novel associated pathways. 
We hypothesise that these metabolic pathways converge 
in tumour cells, where particular metabolic pathways are 
favoured differentially between breast cancer subtypes.
In this study, hBCATm was found to be significantly 
associated with IDH1 expression, indicating that these 
two metabolic pathways are activated concomitantly. 
Expression of hBCATm and IDH1 correlated with lumi-
nal A breast cancer and smaller breast tumours, indicat-
ing better prognosis. Differentially, hBCATc expression 
was found to be significantly associated with the more 
aggressive HER2 + and luminal B subtypes identifying 
subtype-dependent metabolic liabilities. Understanding 
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the metabolic profiles of the different subtypes of breast 
cancer could provide novel tailored therapeutic targets.
Materials and methods
Materials
Rabbit-raised monoclonal antibody to IDH1 was purchased 
from Abcam (Cambridge, UK). Rabbit-raised monoclonal 
antibody to hBCATc and hBCATm was purchased from 
Insight Biotechnology Limited (Wembley, UK). ImmPACT 
DAB Peroxidase (HRP) Substrate and Vectastain elite ABC 
kit were purchased from Vector Labs (Peterborough, UK). 
DPX-mountant, Harris’s Haematoxylin, were purchased 
from Sigma-Aldrich (Dorset, UK). All other chemicals were 
purchased from Thermo Fisher Scientific (Loughborough, 
UK).
Breast cancer tissue samples
Archival human breast cancer tissue samples from surgical 
resections of breast tumours were obtained from the Bristol 
Royal Infirmary under ethical approval from NHS Health 
Research Authority and University of the West of England, 
Ethics Committee (Ref. 11/SW/0127). To re-confirm phe-
notype, all cases were IHC stained for ER, PR, HER2 and 
Ki67. Luminal A breast cancer was classified as tumours 
with ER/PR-positive staining, low Ki67 (< 20%) levels and 
negative for HER2 overexpression, whilst luminal B breast 
cancer was defined as ER/PR-positive, HER2-negative/posi-
tive with high Ki67 (20%). HER2 breast cancer subtype was 
defined in tumours with negative ER/PR and HER2 overex-
pression. Breast tumours which lacked expression of ER/
PR and overexpression of HER2 were defined as TNBC. 
The patient cohort consisted of a total of 83 breast cancer 
cases which were classified into subtypes: HER2 + subtype 
(18 cases), luminal A (19 cases), luminal B (10 cases) and 
TNBC (36 cases). Patients’ clinical pathological characteris-
tics included hormone receptor status, tumour stage, lymph-
node metastasis and survival (Table 1).
Immunohistochemical staining and scoring
Formalin-fixed, paraffin-embedded (FFPE) tissues were seri-
ally sectioned at 4 µm using a microtome (Leica RM2235) 
and mounted on Superfrost Plus slides (Thermo Fisher Sci-
entific, Loughborough, UK). Tissue sections were depar-
affinised in histoclear (National Diagnostics, Atlanta, GA, 
USA) and rehydrated using a series of ethanol concentra-
tions and  dH2O. Endogenous peroxidase was quenched in 
3% v/v hydrogen peroxide for 10 min at room tempera-
ture. Antigen retrieval was performed by heating sections 
in 10 mM citrate buffer pH 6.0 boiled at 95 °C for 30 min 
using a water bath and then allowing the sections to cool to 
room temperature in the buffer. Non-specific binding sites 
were blocked with 5% horse serum in Tris-buffered saline 
(TBS) (200 mM sodium chloride, 2 mM tris, pH 7.5) for 
1 h at room temperature and sections were incubated with 
primary antibody (1:200 for hBCATc, 1:800 hBCATm and 
1:400 IDH1) in blocking serum overnight at 4 °C. Rabbit 
polyclonal antibody raised to hBCATc and rabbit polyclonal 
antibody hBCATm were obtained from Insight Biotechnol-
ogy Limited (Wembley, UK) and rabbit polyclonal antibody 
raised to IDH1 was obtained from Abcam (Cambridge, UK). 
Sections were washed twice with TBS and incubated with 
biotinylated antibody to IgG in TBS for 1 h followed by 
avidin–biotin complex in TBS incubation for 30 min (Vec-
tastain ABC kit; Vector Laboratories, Peterborough, UK). 
Slides were subsequently developed with 3,3′-diaminoben-
zidine (ImmPACT DAB Peroxidase (HRP) Substrate DAB; 
Vector Laboratories, Peterborough, UK) for 10 min. Sec-
tions were counter-stained with Haematoxylin (25% w/v 
Harris’s Haematoxylin). Slides were then dehydrated with 
graded ethanol, cleared in histoclear and mounted using 
DPX (Sigma-Aldrich, Dorset, UK). Secondary antibody and 
only controls were included. The sections were examined on 
a light microscope and scored using the IRS scoring system 
as described in Table 2. Independent scoring was performed 
by two immunohistochemists to validate the score assigned. 
Representative images were captured on a Nikon Eclipse 80i 
(Nikon UK, Kingston Upon Thames, UK).
Statistical analysis
Immunohistochemical data were analysed using SPSS (Ver-
sion 23; SPSS Inc., Chicago, IL, USA) for Mac. Statistical 
significance was reported when p < 0.05. Chi-square was 
used to analyse associations between breast cancer subtypes 
and clinicopathological characteristics. Linear-by-linear 
association was used to investigate the relationship between 
the expression of the metabolic proteins and clinicopatho-
logical characteristics. The Kruskal–Wallis test was used 
to assess age differences between breast cancer subtypes. 
Kaplan–Meier survival curves and log-rank statistics were 
used to evaluate time to tumour recurrence and overall 
survival.
Results
Scoring of protein expression of the various metabolic 
proteins in the human breast cancer tissue was conducted 
using the IRS scoring system as described in Table 2. To 
allow comparability, the intensity scores were adjusted 
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with a score of 4 allocated to the highest intensity and 
1 for the lowest positive signal, to account for variation 
of antibody and protein expression for each of the meta-
bolic proteins as illustrated in Fig. 1. More than 75% 
of cases showed positive expression for the metabolic 
proteins tested (Table 3). Analysis using the IRS scoring 
system allowed associations between the percentage and 
the intensity of protein expression with clinical param-
eters and co-expression of the markers to be elucidated 
in this study.
hBCATc expression associated with HER2 + breast 
cancer subtype and receptor status
The expression of hBCATc was assessed in a total of 75 
primary breast cancer cases using immunohistochemis-
try (Table 3). 62.7% of cases were positive for hBCATc 
expression. Differential expression of hBCATc was 
observed between the subtypes of breast cancer. HER2-
subtype tumours showed significantly higher percentage 
Table 1  Clinicopathological characteristics of the patient cohort according to breast cancer subtypes
Significant p values are indicated in bold
Kruskal–Wallis test was used to assess significant differences for age and linear by linear association used for statistical analysis of all other 
parameters
Parameters Total
(n = 83) (%)
TNBC
(n = 36) (%)
Luminal A
(n = 19) (%)
Luminal B  
(n = 10) (%)
HER2
(n = 18) (%)
p value
Age
(year, mean ± SD)
61.04 ± 13.1 62.85 ± 13.0 61.06 ± 14.0 55.59 ± 16.3 60.44 ± 10.0 0.6799
ER < 0.001
 Negative 52 (64.2) 35 (100.0) 1 (5.3) 1 (10.0) 15 (88.2)
 Positive 29 (35.8) 0 (0.0) 18 (94.7) 9 (90.0) 2 (11.8)
PR < 0.001
 Negative 58 (71.6) 35 (100.0) 5 (26.3) 3 (30.0) 15 (88.2)
 Positive 23 (28.4) 0 (0.0) 14 (73.7) 7 (70.0) 2 (11.8)
HER2 < 0.001
 Negative 57 (70.4) 35 (100.0) 15 (78.9) 5 (50.0) 2 (11.8)
 Positive 24 (29.6) 0 (0.0) 4 (21.0) 5 (50.0) 15 (88.2)
Tumour type 0.159
 Lobular 9 (10.8) 6 (16.7) 3 (15.8) 0 (0.0) 0 (0.0)
 Ductal 68 (81.9) 27 (75.0) 15 (78.9) 8 (80.0) 18 (100)
 Mixed/other 6 (7.2) 3 (8.3) 1 (5.3) 2 (20.0) 0 (0.0)
Histological grade < 0.001
 I/II 42 (50.6) 11 (30.6) 18 (94.7) 6 (60.0) 7 (38.9)
 III 41 (49.4) 25 (69.4) 1 (5.3) 4 (40.0) 11 (61.1)
Tumour stage 0.208
 T1 43 (52.4) 17 (48.6) 14 (73.7) 4 (40.0) 8 (44.4)
 T2 34 (41.5) 16 (45.7) 3 (15.8) 5 (50.0) 10 (55.6)
 T3 5 (6.1) 2 (5.7) 2 (10.5) 1 (10.0) 0 (0.0)
Nodal stage 0.074
 N0 54 (65.9) 25 (71.4) 15 (78.9) 5 (50.0) 9 (50.0)
 N1 18 (22.0) 6 (17.1) 2 (10.5) 3 (30.0) 7 (38.9)
 N2 7 (8.5) 3 (8.6) 2 (10.5) 0 (0.0) 2 (11.1)
 N3 3 (3.7) 1 (2.9) 0 (0.0) 2 (20.0) 0 (0.0) 0.03
TNM stage
 I 35 (42.7) 15 (42.9) 13 (68.4) 4 (40.0) 3 (16.7)
 II 35 (42.7) 15 (42.9) 4 (21.1) 3 (30.0) 13 (72.2)
 III 12 (14.6) 5 (14.3) 2 (10.5) 3 (30.0) 2 (11.1)
Tumour size (cm) 0.162
 ≤ 2 46 (57.5) 18 (52.9) 13 (68.4) 8 (80.0) 7 (41.2)
 > 2 34 (42.5) 16 (47.1) 6 (31.6) 2 (20.0) 10 (58.8)
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of expression and staining intensity of hBCATc (p = 0.044 
and p = 0.036) (Fig. 2a and b). Luminal B tumours also 
presented with a higher percentage of cells expressing 
hBCATc (p = 0.013) compared with luminal A and TNBC 
(Fig. 2a). There was no association of hBCATc intensity 
and ER status (p = 0.601) (Fig. 2c) whilst higher hBCATc 
intensity was present in HER2 receptor-positive tumours 
(p = 0.062) (Fig. 2d) suggesting an association of hBCATc 
with the expression of the HER2 receptor. Triple-negative 
breast cancer cases showed a significantly lower proportion 
of cells expressing hBCATc as shown in Fig. 2e compared 
with the other breast cancer subtypes (p = 0.011). Together, 
these findings show hBCATc is increased in HER2-ampli-
fied breast cancer tumours.
hBCATm and IDH1 expression associated 
with luminal B breast cancer subtype and ER/PR 
receptor status
The expression of hBCATm and IDH1 was positive in 
88.3% and 90.8% of primary breast cancer cases, respec-
tively (Table 3). Whilst hBCATc expression was found to 
be associated with HER2 subtype, expression of hBCATm 
and IDH1 metabolic proteins was found to be significantly 
increased in luminal A tumours compared with other breast 
cancer subtypes. Luminal A tumours expressed a higher 
level of hBCATm expression (Fig. 3b) with an association 
to ER status (p = 0.023) with no association to HER2 status 
(p = 0.319) (Fig. 3c and d). Although the proportion of cells 
expressing hBCATm did not significantly differ between 
tumour subtypes, luminal A tumour cells expressed a higher 
intensity of hBCATm expression (p = 0.017) (Fig. 3b) with 
a significant association to ER-positive status (p = 0.023) 
(Fig. 3c and e). Triple-negative breast cancer cases pre-
sented with significantly lower levels of hBCATm expres-
sion (p = 0.031).
Similar to hBCATm expression, IDH1 staining intensity 
was significantly higher in luminal A tumours (p = 0.044), 
whilst the proportion of cells expressing IDH1 did not dif-
fer between breast cancer subtypes as shown in Fig. 4a 
and b. IDH1 intensity associated with ER-positive status 
(p = 0.044) (Fig. 4c). In contrast, IDH1 intensity did not 
associate with HER2-positive status (p = 0.391) (Fig. 4d) 
and was lowest in the HER2 subtype (p = 0.031) (Fig. 4e). 
Hence, IDH1 expression association with luminal A subtype 
was confirmed to be associated with ER-positive expression 
rather than HER2-positive status. The differential expression 
of the hBCAT and IDH1 proteins between the breast cancer 
subtypes is represented in Fig. 5. Serial sections showed 
hBCATm and IDH1 to be expressed in the same cells indi-
cating that their co-expression is important in the luminal 
A subtype, this association was found to be significant for 
both percentage and intensity of staining (p = 0.018 and 
p = 0.037) (Fig. 6).
Association of metabolic enzymes to patient 
clinicopathological characteristics
Statistical analysis was performed to assess the association 
between the expression of metabolic proteins; hBCATc, 
hBCATm and IDH1 to clinicopathological features 
Table 2  IRS and nuclear expression scoring system
Percentage of positive cells Intensity of staining IRS class (0–12)
0 = no positive cells 0 = no reaction 0–1 = negative
1 ≤ 10% of positive cells 1 = mild reaction 2–3 = mild
2 = 10–50% positive cells 2 = moderate reaction 4–8 = moderate
3 = 51–80% positive cells 3 = intense reaction 9–12 = strongly positive
4 ≥ 80% positive cells
IRS—points IRS classification (0–3)
0–1 0 = negative
2–3 1 = positive, weak expression
4–8 2 = positive, moderate expression
9–12 3 = positive, strong expression
Nuclear - score Nuclear expression (0-3)
0 No nuclear staining
1 < 10% of tumour cells have nuclear staining
2 10-50% of tumour cells have nuclear staining
3 ≥ 51% of tumour cells have nuclear staining
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Fig. 1  Representative images of 
the intensity of immune reac-
tion for each of the metabolic 
proteins, as indicated, in human 
breast cancer sections. Slides 
were scored using the IRS 
scoring system and images 
captured by Leica microscope 




(Tables 4, 5 and 6). Although expression of these metabolic 
proteins did not significantly associate with disease-free 
survival (Fig. 7), hBCATm was found to be significantly 
associated with smaller tumours (i = 0.029) with 91.8% of 
tumours ≤ 2 cm displaying moderate-to-strong IRS class 
compared with 73.4% of tumours > 2 cm. Similarly, IDH1 
IRS class is significantly associated (p = 0.013) with small 
tumour size with 47.7% of larger tumours displaying strong 
IRS and only 20% of smaller tumours had a strong IRS class. 
IDH1 IRS class also associated with no lymph node invasion 
with 90.9% of cases having strong IRS. Lower histologi-
cal grades were associated with strong IRS class of IDH1, 
46.3% of cases compared with 22.9% of grade 3 tumours. 
Moreover, IDH1 strong IRS class also associated with lower 
TNM staging, in 52.9% of stage I tumours.
Discussion
HER2 subtype, characterised by overexpression of its 
HER2 transmembrane receptor protein, is a higher-grade 
tumour with a more aggressive phenotype and worse prog-
nosis relative to luminal A subtypes. Understanding the 
phenotypic profiling of breast cancer tumours is essential 
as it informs treatment regimens especially as different 
subtypes have distinct locoregional patterns [34]. Lumi-
nal A subtypes are at the lower risk of locoregional fail-
ure, and HER2-positive and TNBC at the higher risk. In 
this study, we show differential metabolic protein profiles 
for luminal A and HER2 tumour subtypes. A significant 
Table 3  Table presenting the number of positive and negative breast 
cancer sections for each of the metabolic markers from total cases 
assessed
Negative (%) Positive (%) Total
hBCATc 28 (37.3) 47 (62.7) 75
hBCATm 9 (11.7) 68 (88.3) 77
IDH1 7 (9.2) 69 (90.8) 76
Fig. 2  Proportion of cells 
expressing hBCATc and 
intensity of reaction was 
significantly associated with 
HER2 subtype. a, b Bar chart 
showing the percentage of cases 
of hBCATc (a) proportion and 
(b) intensity of the immunore-
activity for each of the subtypes 
of breast cancer (c) bar chart of 
percentage of hBCATc staining 
intensity between ER receptor 
negative and positive tumours 
(d) bar chart of percentage 
of hBCATc staining intensity 
between HER2 receptor nega-
tive and positive tumours (e) 
summary of the p values for the 
chi-square linear-by-linear test 
of association for hBCATc pro-
portion and intensity association 
to TNBC, luminal A, luminal B 
and HER2 subtypes and to ER 
and HER2 receptor status
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positive association between HER2 status and hBCATc 
was observed (Fig. 2) where, HER2 + breast cancer and 
TNBC subtypes demonstrated higher histopathological 
grading (p < 0.001) than the other subtypes (Table 1), 
indicating hBCATc expression is elevated in more aggres-
sive tumours. Thewes et al. [23] have previously shown an 
upregulation of hBCATc in breast cancer tissue samples in 
ER-tumours, particularly TNBC and HER2 + subtype. In 
the cohort assessed, a significant association of hBCATc 
expression with HER2 + and luminal B breast cancer sub-
types was demonstrated (Fig. 2). Whilst luminal B tumours 
may or may not overexpress HER2, hBCATc expression 
significantly associated with HER2 status which encom-
passes luminal B tumours with HER2 amplification, indi-
cating HER2 receptor signalling in tumour may regulate 
hBCATc expression.
SKBR3 cells, which are a well-known breast cancer cell 
model for HER2 + subtype, have been characterised to lack 
hBCATc expression [23, 35]. Genome-wide proteomics of 
breast cancer cell lines, including SKBR3, reported hBCATc 
to correlate with higher levels of epidermal growth factor 
receptor (EGFR) expression, which is upregulated in TNBC, 
but not in HER2-positive breast cancer [35]. Conversely, 
Wang et al. [19] have demonstrated that hBCATc overex-
pression in the HER2-positive SKOV3 ovarian cancer cells 
contributes to increased cell proliferation, migration and 
invasion, thus facilitating tumour progression. Wilken et al. 
[36] found Herceptin, which is a commonly used HER2-
targeted therapy, sensitised ovarian cancer (SKOV3) cells 
to EGFR-targeted therapy. Therefore, it is possible that ele-
vated hBCATc expression observed in the HER2 breast can-
cer subtypes in vivo occurs in response to standard patient 
therapy. This suggests that the current breast cancer cell line 
models of HER2 + subtype do not reflect the pathophysio-
logical process which has been observed in the human breast 
cancer tissue.
Despite the established link between c-Myc amplification 
and HER2 subtype, there are currently no studies directly 
attributing HER2 receptor amplification with hBCATc, 
which is up-regulated by c-Myc [37]. In contrast, much 
Fig. 3  Proportion of cells 
expressing hBCATm was 
significantly associated with 
Luminal A subtype and ER 
receptor status. a, b Bar chart 
showing the percentage of cases 
of hBCATm (a) proportion and 
(b) intensity of the immunore-
activity for each of the subtypes 
of breast cancer (c) bar chart of 
percentage of hBCATm staining 
intensity between ER receptor 
negative and positive tumours 
(d) bar chart of percentage of 
hBCATm staining intensity 
between HER2 receptor nega-
tive and positive tumours (e) 
summary of the p values for the 
chi-square linear-by-linear test 
of association for hBCATm pro-
portion and intensity associated 
to TNBC, luminal A, luminal B 
and HER2 subtypes and to ER 
and HER2 receptor status
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work has focused on re-programmed glutamine metabolism 
in cancer cells which promotes tumour energy generation, 
survival and growth [38]. Increased glutamine metabolic 
activity has been observed in HER2-positive breast can-
cer tissue compared with other subtypes of breast cancer, 
through upregulation of glutamine metabolic proteins 
including glutaminase 1 (GLS1) and glutamate dehydroge-
nase (GDH) [39, 40]. Furthermore, HER2 receptor induc-
tion in MCF-10A cells instigated upregulation of GLS1 and 
increased cell proliferation [41] establishing a direct role of 
HER2 in elevated glutamate synthesis. The transamination 
of BCAAs by hBCATc leads to the production of glutamate 
and the TCA intermediates acetyl-coA and succinyl-coA, 
which may be required to sustain tumour growth in this con-
text. Glutamate offers multiple benefits to tumour growth 
as reviewed by [42] and elevated levels have been associ-
ated with breast cancer metastasis [43]. This indicates that 
hBCATc can function in conjunction with glutaminase to 
enhance glutamate flux to tumour cells and fuel cell growth 
through the TCA cycle. In addition to metabolite regulation, 
ligand binding to HER2 can activate the PI3K/Akt pathway, 
where a role for activated Akt in tumorigenesis is widely 
recognised. As discussed, we have evidenced that BCATc 
regulates cell proliferation and migration through activa-
tion of the PI3K/Akt pathway, whilst suppressing Ras/ERK 
activation, highlighting the plasticity of tumours to advance 
and adapt to changing environments [26], in particular in 
response to HER2 activation.
Although, immunohistochemical analysis of hBCATc 
expression in this cohort of breast cancer patients demon-
strated a negative association with TNBC tumours (Fig. 2E), 
there was positive expression in 50% of the 32 TNBC cases 
assessed. Thewes et al. [23] have previously demonstrated an 
upregulation of hBCATc in a larger study in TNBC, whereby 
75% of 109 TNBC tumours were positive for hBCATc 
expression. Moreover, expression of hBCATc has been 
demonstrated to be limited to the TNBC (MDA-MB-231) 
cells in a panel of breast cancer cell lines [23], further 
Fig. 4  Proportion of cells 
expressing IDH1 intensity of 
reaction was significantly asso-
ciated with Luminal A subtype. 
a, b Bar chart showing the 
percentage of cases of IDH1 (a) 
proportion and (b) intensity of 
the immunoreactivity for each 
of the subtypes of breast cancer 
(c) bar chart of percentage of 
IDH1 staining intensity between 
ER receptor negative and 
positive tumours (d) bar chart 
of percentage of IDH1 stain-
ing intensity between HER2 
receptor negative and positive 
tumours (e) summary of the 
p values for the Chi-square 
linear-by-linear test of associa-
tion for IDH1 proportion and 
intensity association to TNBC, 
luminal A, luminal B and HER2 




supporting a role for hBCATc in more aggressive subtypes. 
In gliomas, 2HG, which is a competitive inhibitor of mul-
tiple α-KG-dependent dioxygenases, produced by mutant-
IDH1, has been found to inhibit BCAT1 and BCAT2 [31, 44]. 
Metabolomic analysis reported elevated levels of 2HG in 
the absence of IDH-mutations in MDA-MB-231 cells [32]. 
Elevated level of 2HG has been shown to promote H3K79 
dimethylation [44]. Interestingly, BCAT1 expression was 
upregulated by DOT1L-mediated histone dimethylation of 
H3K79 in MDA-MB-231 cells [45]. Thus, in breast cancer, 
epigenetic regulation mediated by 2HG and DOT1L may 
upregulate hBCATc in TNBC, which has been demonstrated 
to mediate proliferation and migration in breast cancer [23].
There is little evidence of IDH1 mutations in breast can-
cer, with only one reported case discussed in the literature 
[32, 33]. Levels of 2HG are significantly increased in ER-
tumours and breast cancer cell lines [32]. However, the 
only case of IDH1 mutation was found to be reported in 
Fig. 5  Representative images of the hBCAT and IDH1 proteins in dif-
ferent molecular breast cancer subtypes. hBCATc levels were signifi-
cantly elevated in the HER-2 subtype and Luminal B subtypes. Lumi-
nal A subtype was characterised with increased levels of hBCATm 
and IDH1. × 10 objective (scale bars = 25 μm)
Fig. 6  hBCATm and IDH1 
co-expression was found to 
be significantly significant. a 
Co-expression of hBCATm and 
IDH1 was observed in the same 
cells. b Table showing the linear 
by linear p-values for hBCATm 
proportion, intensity and IRS 
class association with IDH1 




ER + breast cancer [33] indicating IDH1 mutations to be a 
rare event in breast cancer. The IDH enzymes are responsi-
ble for the oxidative decarboxylation of isocitrate to produce 
α-ketoglutarate [46, 47]. IDH1 acts as a major source of 
cytosolic NADPH production required for multiple meta-
bolic pathways, including glutathione production and fatty 
acid biosynthesis [48]. Low expression of IDH1 has been 
associated with poor prognosis in breast cancer, whilst high 
expression of IDH1 associated with better survival indicat-
ing that IDH1 acts as a tumour suppressor in breast cancer 
[49]. Correspondingly higher expression of IDH1 was found 
to be significantly associated with smaller tumour size, lower 
tumour stage and histological grade (Table 6) suggesting 
that IDH1 expression is indicative of a positive prognostic 
outcome.
For the first time, luminal A tumours were characterised 
by increased expression of hBCATm and IDH1 (Figs. 3 
and 4). hBCATm was found to be significantly associated 
with IDH1 expression (Fig. 6), suggesting these two meta-
bolic pathways are activated concomitantly. Indeed, sterol 
response element-binding protein 1 (SREBP1) has been 
demonstrated to regulate hBCATm, in pancreatic ductal 
adenocarcinoma [50] and IDH1, but not IDH2 expression, 
in breast cancer [51]. SREBP-1 is a transcription factor 
which activates genes involved in fatty acid synthesis and is 
reported to be upregulated in breast cancer [52]. Oestrogen 
stimulation in ER-positive (MCF7) cells has been shown 
to induce SREBP1 expression [53]. Knockdown of BCAT2 
in oestrogen receptor-positive (MCF7) cells was shown to 
result in reduced proliferation in contrast to normal-like 
MCF-10A breast cells and airway smooth muscle (ASM) 
cells where no effect on cell proliferation was observed [54] 
indicating tumour-selective BCAT2-mediated inhibition of 
cell growth.
Moreover, elevated oxidative stress in tumour cells can 
induce AMPK activation, which inhibits SREBP1 [55]. 
The thiol regions of the CXXC motif in hBCATc exhibit 
sensitivity to changes in the redox environment [56]. The 
hBCAT proteins contribute to glutathione (GSH) biosynthe-
sis, by facilitating the uptake of cystine via the  xc-cysteine 
Table 4  Associations between hBCATc expression and clinicopathological characteristics
Linear by linear association was used for statistical analysis












 Lobular 3 (42.9) 1 (14.3) 2 (28.6) 1 (14.3) 7
 Ductal 25 (40.3) 11 (17.7) 17 (27.4) 9 (14.5) 62
 Mixed/other 0 (0.0) 2 (33.3) 3 (50.0) 1 (16.7) 6
Histological grade 0.852
 I/II 16 (43.2) 2 (5.4) 15 (40.5) 4 (10.8) 37
 III 12 (31.6) 12 (31.6) 7 (18.4) 7 (18.4) 38
Tumour stage 0.163
 T1 19 (48.7) 3 (7.7) 13 (33.3) 4 (10.3) 39
 T2 9 (27.3) 10 (30.3) 7 (21.2) 7 (21.2) 33
 T3 0 (0.0) 1 (33.3) 2 (66.7) 0 (0.0) 3
Nodal stage 0.989
 N0 20 (40.8) 7 (14.3) 14 (28.6) 8 (16.3) 49
 N1 6 (33.3) 3 (16.7) 7 (38.9) 2 (11.1) 18
 N2 1 (20.0) 3 (60.0) 1 (20.0) 0 (0.0) 5
 N3 1 (33.3) 1 (33.3) 0 (0.0) 1 (33.3) 3
Tumour stage (TNM) 0.254
 I 16 (51.6) 2 (6.5) 11 (35.5) 2 (6.5) 31
 II 10 (29.4) 7 (20.6) 9 (26.5) 8 (23.5) 34
 III 2 (20.0) 5 (50.0) 2 (20.0) 1 (10.0) 10
Tumour size (cm) 0.177
 ≤ 2 20 (46.5) 5 (11.6) 14 (32.6) 4 (9.3) 43
 > 2 8 (26.7) 8 (26.7) 8 (26.7) 6 (20.0) 30
Lymph node invasion 0.461
 No 19 (38.0) 7 (14.0) 15 (30.0) 9 (18.0) 50
 Yes 9 (36.0) 7 (28.0) 7 (28.0) 2 (8.0) 25
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transporter, which is coupled to the efflux of glutamate [31, 
38]. GSH plays an important role in redox homeostasis 
and tumour cell survival by protecting cells from damage 
caused by the reactive oxygen species (ROS) generated 
during oxidative stress [57]. Moreover, expression levels of 
hBCAT have been demonstrated to regulate the expression 
of nuclear factor (erythroid-derived 2)-like-2 (Nrf2), which 
is the primary transcription factor responsible for the regula-
tion of genes encoding oxidative stress‐related proteins [26]. 
Hence, increased expression of hBCATm in the luminal A 
subtype is suggested to reduce ROS levels, thereby provid-
ing a mechanistic positive feedback loop which enhances 
SREBP1-induced IDH1 and hBCATm upregulation. In glio-
mas, hBCATm has been identified as a negative prognostic 
marker in IDH1-WT gliomas [18], supporting the hypoth-
esis for hBCATm to contribute to tumour progression in the 
absence of IDH mutation, which is a rare event in breast 
cancer [32, 33]. IDH1 is responsible for the oxidative car-
boxylation of isocitrate to maintain levels of α-ketoglutarate 
in the cytosol which is critical for the TCA cycle [58]. Con-
versely, hBCATm utilises α-ketoglutarate in the transamina-
tion of BCAAs in the mitochondria. Consequently, enhanced 
expression of IDH1 may replenish the α-ketoglutarate pool 
in cells with increased hBCATm, which can then be shut-
tled to the mitochondria via the membrane transporter 
SLC25A11 [58], to support the TCA cycle. Therefore, IDH1 
and hBCATm metabolism can be proposed to work in con-
junction to support tumour growth in luminal A tumours.
Conclusion
In this study, hBCATc expression was found to be signifi-
cantly associated with the more aggressive HER2 + and 
luminal B subtype whilst hBCATm and IDH1 to be signifi-
cantly associated with luminal A subtype suggesting differ-
ential metabolic reliance between these two subtypes. For 
the first time a synergistic mechanistic expression of IDH1 
Table 5  Associations between hBCATm expression and clinicopathological characteristics
Linear by linear association was used for statistical analysis












 Lobular 1 (11.1) 1 (11.1) 5 (55.6) 2 (22.2) 9
 Ductal 7 (11.3) 2 (3.2) 34 (54.8) 19 (30.6) 62
 Mixed/other 1 (16.7) 0 (0.0) 3 (50.0) 2 (33.3) 6
Histological grade 0.078
 I/II 2 (5.1) 1 (2.6) 23 (59.0) 13 (33.3) 39
 III 7 (18.4) 2 (5.3) 19 (50.0) 10 (26.3) 38
Tumour stage 0.147
 T1 4 (9.8) 0 (0.0) 21 (51.2) 16 (39.0) 41
 T2 5 (16.1) 2 (6.5) 18 (58.1) 6 (19.4) 31
 T3 0 (0.0) 1 (20.0) 3 (60.0) 1 (20.0) 5
Nodal stage 0.348
 N0 5 (10.2) 1 (2.0) 27 (55.1) 16 (32.7) 49
 N1 3 (16.7) 1 (5.6) 10 (55.6) 4 (22.2) 18
 N2 0 (0) 1 (14.3) 3 (42.9) 3 (42.9) 7
 N3 1 (33.0) 0 (0.0) 2 (66.7) 0 (0) 3
Tumour stage (TNM) 0.254
 I 3 (9.1) 0 (0.0) 17 (51.5) 13 (39.4) 33
 II 5 (15.6) 2 (6.3) 18 (56.3) 7 (21.9) 32
 III 51 (8.3) 1 (8.3) 7 (58.3) 3 (25.0) 12
Tumour size (cm) 0.029
 ≤ 2 4 (8.9) 0 (0.0) 24 (53.3) 17 (37.8) 45
 > 2 5 (16.7) 3 (10.0) 17 (56.7) 5 (16.7) 30
Lymph node invasion 0.937
 No 7 (14.0) 1 (2.0) 26 (52.0) 16 (32.0) 50
 Yes 2 (7.4) 2 (7.4) 16 (59.3) 7 (25.9) 27
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and hBCATm in luminal A breast cancer has been described, 
which may be mediated by upregulation of the ER-activated 
SREBP1 transcription factor. Further work is needed to 
understand the mechanism by which HER2 may regulate 
hBCATc expression and the metabolic benefits hBCATc may 
offer to these tumours. Metabolic rewiring in breast cancer 
is suggested to be dependent on hormone and HER2 recep-
tor expression. Thus, understanding these metabolic profiles 
will help provide subtype-specific therapeutic targets.
Table 6  Associations between of IDH1 expression and clinicopathological characteristics
Significant p values are indicated in bold
Linear by linear association was used for statistical analysis












 Lobular 0 (0.0) 1 (11.1) 4 (44.4) 4 (44.4) 9
 Ductal 7 (11.5) 4 (6.6) 29 (47.5) 21 (34.4) 61
 Mixed/other 0 (0.0) 0 (0.0) 4 (66.7) 2 (33.3) 6
Histological grade 0.046
 I/II 2 (4.9) 3 (7.3) 17 (41.5) 19 (46.3) 41
 III 5 (14.3) 2 (5.7) 20 (57.1) 8 (22.9) 35
Tumour stage 0.079
 T1 2 (4.9) 2 (4.9) 18 (43.9) 19 (46.3) 41
 T2 5 (16.1) 3 (9.7) 16 (51.6) 7 (22.6) 31
 T3 0 (0.0) 0 (0.0) 3 (75.0) 1 (25.0) 4
Nodal stage 0.077
 N0 2 (4.0) 4 (8.0) 21 (42.0) 23 (46.0) 50
 N1 4 (23.5) 0 (0.0) 11 (64.7) 2 (11.8) 17
 N2 1 (16.7) 1 (16.7) 3 (50.0) 1 (16.7) 6
 N3 0 (0.0) 0 (0.0) 2 (66.7) 1 (33.3) 3
Tumour stage (TNM) 0.022
 I 1 (2.9) 2 (5.9) 13 (38.2) 18 (52.9) 34
 II 5 (16.1) 2 (6.5) 17 (54.8) 7 (22.6) 31
 III 1 (9.1) 1 (9.1) 7 (63.6) 2 (18.2) 11
Tumour size (cm) 0.013
 ≤ 2 2 (4.5) 2 (4.5) 19 (43.2) 21 (47.7) 44
 > 2 4 (13.3) 3 (10.0) 17 (56.7) 6 (20.0) 30
Lymph node invasion 0.018
 No 3 (5.9) 4 (7.8) 20 (39.2) 24 (47.1) 51
 Yes 4 (16.0) 1 (4.0) 17 (68.0) 3 (12.0) 25
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